The role of Eph/ephrin molecules in stromal–hematopoietic interactions

International Journal of Hematology

Volumn 103, Issue 2, 2016, Pages 145-154

  Nguyen, Thao M ^a,b   Arthur, Agnieszka ^a,b,c   Gronthos, Stan ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c Division of Haematology   (Australia)

Author keywords

Bone marrow mesenchymal stem cells; Eph receptors; Ephrin ligands; Haematopoietic stem cells niche; Stromal cells

Indexed keywords

EPHRIN; EPHRIN RECEPTOR A1; LIGAND;

ANIMAL; CELL COMMUNICATION; GENETICS; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PHYSIOLOGY;

ANIMALS; CELL COMMUNICATION; EPHRINS; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LIGANDS; MESENCHYMAL STROMAL CELLS; MICE; MOLECULAR TARGETED THERAPY; RECEPTOR, EPHA1;

EID: 84955640823     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1886-x     Document Type: Review

References (82)

1. Hirai H, Maru Y, Hagiwara K, Nishida J, Takadu F. A novel putative tyrosine kinase receptor encoded by the eph gene. Science. 1987;238:1717–20.
2. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol. 1997;9(5):608–15.
3. Nagano K, S-i Kanasaki, Yamashita T, Maeda Y, Inoue M, Higashisaka K, et al. Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. Cancer Med. 2013;2(6):972–7.
4. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002;3:475–86.
5. Himanen JP, Saha N, Nikolov DB. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol. 2007;19(5):534–42.
6. Nguyen TM, Arthur A, Hayball JD, Gronthos S. EphB and ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells. Stem Cells Dev. 2013;22(20):2751–64.
7. Arthur A, Panagopoulos RA, Cooper L, Menicanin D, Parkinson IH, Codrington JD, et al. EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. J Bone Miner Res. 2013;28(4):926–35.
8. Arthur A, Zannettino A, Panagopoulos R, Kobla S, Sims NA, Stylianou C, et al. EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone. 2011;48:533–42.
9. Arthur A, Koblar S, Shi S, Gronthos S. Eph/ephrinB mediate dental pulp stem cell mobilization and function. J Dent Res. 2009;88(9):829–34.
10. Pasquale EB. Eph receptor signaling casts a wide net on cell behaviour. Nat Rev. 2005;6:462–75.
11. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133(1):38–52.
12. Murai KK, Pasquale EB. ‘Eph’ective signaling: forward, reverse and crosstalk. J Cell Sci. 2003;116:2823–32.
13. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165–80.
14. Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nature. 2014;13:39–62.
15. Furukawa K, Sato T, Katsuno T, Nakagawa T, Noguchi Y, Tokumasa A, et al. Smad3 contributes to positioning of proliferating cells in colonic crypts by inducing EphB receptor protein expression. Biochem Biophys Res Commun. 2011;405(4):521–6.
16. Gerety SS, Wang HU, Chen Z, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell. 1999;4(3):403–14.
17. Stokowski A, Shi S, Sun T, Bartold P, Koblar S, Gronthos S. EphB/ephrinB interaction mediates adult stem cell attachment, spreading, and migration: implications for dental tissue repair. Stem Cells. 2007;25:156–64.
18. Matsuo K, Otaki N. Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adhes Migr. 2012;6(2):148–56.
19. Aasheim HC, Delabie J, Finne EF. Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. Blood. 2005;105(7):2869–76.
20. Lazarova P, Wu Q, Kvalheim G, Suo Z, Haakenstad KW, Metodiev K, et al. Growth factor receptors in hematopoietic stem cells: EPH family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood. Int J Immunopathol Pharmacol. 2006;19(1):49–56.
21. Okubo T, Yanai N, Obinata M. Stromal cells modulate ephrinB2 expression and transmigration of hematopoietic cells. Exp Hematol. 2006;34(3):330–8.
22. Prévost N, Woulfe DS, Jiang H, Stalker T, Marchese P, Ruggeri ZM, et al. Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc Natl Acad Sci USA. 2005;102(28):9820–5.
23. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell. 2006;124(1):161–73.
24. Suenobu S, Takakura N, Inada T, Yamada Y, Yuasa H, Zhang XQ, et al. A role of EphB4 receptor and its ligand, ephrin-B2, in erythropoiesis. Biochem Biophys Res Commun. 2002;293(3):1124–31.
25. Ting MJ, Boyd AW. The role of Eph receptor tyrosine kinases and ephrin ligands in hematopoietic cell development and function. Open Hematol. 2008;2:103–10.
26. Ting MJ, Day BW, Spanevello MD, Boyd AW. Activation of ephrin A proteins influences hematopoietic stem cell adhesion and trafficking patterns. Exp Hematol. 2010;38(11):1087–98.
27. Wang Z, Miura N, Bonelli A, Mole P, Carlesso N, Olson DP, et al. Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells. Blood. 2002;99(8):2740–7.
28. Yu G, Luo H, Wu Y, Wu J. EphrinB1 is essential in T-cell-T-cell co-operation during T-cell activation. J Biol Chem. 2004;279(53):55531–9.
29. Eaves C, Miller C, Cashman J, Conneally E, Petzer A, Zandstra P, et al. Hematopoietic stem cells: inferences from in vivo assays. Stem Cells. 1997;15(S2):1–5.
30. − progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. Blood. 1999;93(1):96–106.
31. Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell. 2007;1(2):204–17.
32. Greenbaum A, Hsu YS, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227–30. doi:10.1038/nature11926(2013 03/14/print).
33. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 2013;495(7440):231–5. doi:10.1038/nature11885(2013 03/14/print).
34. Oguro H, Ding L, Morrison SJ. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell. 2013;13(1):102–16.
35. Munoz JJ, Alfaro D, Garcia-Ceca J, Alonso-C LM, Jimenez E, Zapata A. Thymic alterations in EphA4-deficient mice. J Immunol. 2006;177(2):804–13.
36. Arvanitis DN, Jungas T, Behar A, Davy A. Ephrin-B1 reverse signaling controls a posttranscriptional feedback mechanism via miR-124. Mol Cell Biol. 2010;30(10):2508–17.
37. Luo H, Yu G, Wu Y, Wu J. EphB6 crosslinking results in costimulation of T cells. J Clin Invest. 2002;110:1141–50.
38. Sharfe N, Freywald A, Toro A, Dadi H, Roifman C. Ephrin stimulation modulates T cell chemotaxis. Eur J Immunol. 2002;32(12):3745–55.
39. Yu G, Luo H, Wu Y, Wu J. Ephrin B2 induces T Cell costimulation. J Immunol. 2003;171(1):106–14.
40. Aasheim HC, Munthe E, Funderud S, Smeland EB, Beiske K, Logtenberg T. A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes. Blood. 2000;95(1):221–30.
41. Prevost N, Woulfe D, Tanaka T, Brass LF. Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred. Proc Natl Acad Sci USA. 2002;99(14):9219–24.
42. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science. 2002;298(5593):601–4.
43. Steidl U, Bork S, Schaub S, Selbach O, Seres J, Aivado M, et al. Primary human CD34+ hematopoietic stem and progenitor cells express functionally active receptors of neuromediators. Blood. 2004;104(1):81–8.
44. Nguyen TM, Arthur A, Panagopoulos R, Paton S, Hayball JD, Zannettino AC, et al. EphB4 expressing stromal cells exhibit an enhanced capacity for hematopoietic stem cell maintenance. Stem Cells. 2015;33(9):2838–49.
45. Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci. 2003;116:1827–35.
46. Sacchetti B, Funari A, Michienzi S, DiCesare S, Piersanti S, Saggio I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organise a hematopoietic microenvironment. Cell. 2007;131:324–36.
47. Shi S, Gronthos S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res. 2003;18(4):696–704.
48. −/glycophorin-A-bone marrow cells. Haematologica. 2007;92(12):1707–8.
49. Friedenstein AJ, Piatetzky S, Petrakova KV. Osteogenesiss of in transplant of bone marrow cells. J Embryol Exp Morphol. 1966;16:381–90.
50. Friedenstein AJ, Petrakova KV, Kurolesova AL, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230–47.
51. Friedenstein AJ, Chailakhian RK, Laylykina K. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393–403.
52. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the haematopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17:331–40.
53. Short BJ, Brouard N, Simmons PJ. Prospective isolation of mesenchymal stem cells from mouse compact bone. Stem Cell Regen Med. 2009;482(5):259–68.
54. Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem. 2007;282(26):19082–91.
55. Noll JE, Williams SA, Tong CM, Wang H, Quach JM, Purton LE, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2014;99(1):163–71.
56. Winkler IG, Barbier V, Wadley R, Zannettino ACW, Williams S, Lévesque J. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood. 2010;116(3):375–85.
57. Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, et al. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem. 2009;284(21):14637–44.
58. Martin TJ, Allan EH, Ho PWM, Gooi JH, Quinn JMW, Gillespie MT et al. Communication between ephrinB2 and EphB4 within the osteoblast lineage. In: Choi Y, editor. Osteoimmunology. Berlin: Springer; 2010. p 51–60.
59. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4(2):111–21.
60. Xing W, Kim J, Wergedal J, Chen ST, Mohan S. Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. Mol Cell Biol. 2010;30(3):711–21.
61. Twigg SR, Rui K, Babbs C, Bochukova EG, Robertson SP, Wall SA, et al. Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci USA. 2004;101:8652–7.
62. Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, et al. Eph/ephrin signaling in injury and inflammation. Am J Pathol. 2012;181(5):1493–503.
63. Pitulescu ME, Adams RH. Eph/ephrin molecules—a hub for signaling and endocytosis. Genes Dev. 2010;24(22):2480–92.
64. Wieland I, Jakubiczka S, Muschke P, Cohen M, Thiele H, Gerlach KL, et al. Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome. Am J Hum Genet. 2004;74(6):1209–15.
65. Bush JO, Soriano P. Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph–ephrin boundaries. Genes Dev. 2010;24(18):2068–80.
66. Makarov R, Steiner B, Gucev Z, Tasic V, Wieacker P, Wieland I. The impact of CFNS-causing EFNB1 mutations on ephrin-B1 function. BMC Med Genet. 2010;11(1):98.
67. Allan EH, Häusler KD, Wei T, Gooi JH, Quinn JMW, Crimeen-Irwin B, et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res. 2008;23(8):1170–81.
68. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells. 2006;24(4):1030–41.
69. Moore MAS. Hematopoietic stem cells. In: Rajasekhar VK, Vemuri MC, editors. Regulatory networks in stem cells. New York: Humana Press; 2009. p. 347–77.
70. Daar IO. Non-SH2/PDZ reverse signaling by ephrins. Semin Cell Dev Biol. 2012;23(1):65–74.
71. + haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol. 2000;110:71–81.
72. Simmons PJ, Masinovsky B, Longenecker BM, Berenson R, Torok-Storb B, Gallatin WM. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood. 1992;80(2):388–95.
73. Pasquale EB. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci. 2004;7(5):417–8. doi:10.1038/nn0504-417.
74. Scadden DT. Nice neighborhood: emerging concepts of the stem cell niche. Cell. 2014;157(1):41–50.
75. Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, et al. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res. 2014;74(16):4470–81.
76. Janes PW, Slape CI, Farnsworth RH, Atapattu L, Scott AM, Vail ME. EphA3 biology and cancer. Growth Factors. 2014;32(6):176–89.
77. Keane N, Freeman C, Swords R, Giles FJ. EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Rev Hematol. 2012;5(3):325–40.
78. Tomasevic N, Luehrsen K, Baer M, Palath V, Martinez D, Williams J, et al. A high affinity recombinant antibody to the human EphA3 receptor with enhanced ADCC activity. Growth Factors. 2014;32(6):223–35.
79. Garcia-Gomez A, Sanchez-Guijo F, del Cañizo MC, San Miguel JF, Garayoa M. Multiple myeloma mesenchymal stromal cells: contribution to myeloma bone disease and therapeutics. World J Stem Cells. 2014;6(3):1803–12.
80. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Barlogie B, et al. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009;114(9):1803–12.
81. Vandyke K, Chow AWS, Williams SA, To LB, Zannettino ACW. Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. Br J Haematol. 2013;161(4):499–507.
82. Valverde-Franco G, Pelletier JP, Fahmi H, Hum D, Matsuo K, Lussier B, et al. In vivo bone-specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis. Arthritis Rheum. 2012;64(11):3614–25.